Janux Therapeutics (JANX) Net Income (2020 - 2026)
Janux Therapeutics (JANX) reported Net Income of -$24.4 million for Q1 2026, down 3.63% year-over-year from -$25.3 million in Q1 2025, and up 23.74% on a QoQ basis from -$31.9 million in Q4 2025.
Janux Therapeutics (JANX) has 7 years of Net Income data on file, last reported at -$24.4 million in Q1 2026.
- Quarterly Net Income fell 3.63% year-over-year to -$24.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$114.5 million (down 47.25% YoY) and the FY2025 annual result came in at -$113.6 million, down 64.69% from the prior year.
- Net Income climbed to -$24.4 million in Q1 2026 per JANX's latest filing, from -$31.9 million in the prior quarter.
- Across five years, Net Income topped out at -$6.0 million in Q2 2024 and bottomed at -$33.9 million in Q2 2025.
- The 5-year median for Net Income is -$17.5 million (2023), against an average of -$19.3 million.
- The widest annual swing landed in 2022, when Net Income slumped 487.13%; it then jumped 65.96% in 2024.
- Tracing JANX's Net Income over 5 years: stood at -$16.1 million in 2022, then increased by 26.81% to -$11.8 million in 2023, then sank by 71.93% to -$20.2 million in 2024, then sank by 58.02% to -$31.9 million in 2025, then increased by 23.74% to -$24.4 million in 2026.
- Per Business Quant, the three latest JANX Net Income figures stand at -$24.4 million (Q1 2026), -$31.9 million (Q4 2025), and -$24.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Janux Therapeutics | 914.29 Mn | 914.29 Mn | - | -24.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.36 Mn |
| Dec 31, 2025 | -31.95 Mn |
| Sep 30, 2025 | -24.31 Mn |
| Jun 30, 2025 | -33.86 Mn |
| Mar 31, 2025 | -23.51 Mn |
| Dec 31, 2024 | -20.22 Mn |
| Sep 30, 2024 | -28.06 Mn |
| Jun 30, 2024 | -5.96 Mn |
| Mar 31, 2024 | -14.76 Mn |
| Dec 31, 2023 | -11.76 Mn |
| Sep 30, 2023 | -11.57 Mn |
| Jun 30, 2023 | -17.51 Mn |
| Mar 31, 2023 | -17.46 Mn |
| Dec 31, 2022 | -16.07 Mn |
| Sep 30, 2022 | -16.70 Mn |
| Jun 30, 2022 | -16.89 Mn |
| Mar 31, 2022 | -13.41 Mn |
| Dec 31, 2021 | -13.42 Mn |
| Sep 30, 2021 | -10.77 Mn |
| Jun 30, 2021 | -6.21 Mn |
| Mar 31, 2021 | -2.28 Mn |
| Dec 31, 2020 | -1.66 Mn |
| Sep 30, 2020 | -1.26 Mn |
| Jun 30, 2020 | -1.22 Mn |